Vladimir Tkachenko, general manager of AMAXA PHARMA, a UK-headquartered pharmaceutical company focused on life-threatening therapeutic areas such as oncology and neonatology in the CIS countries, provides insights into AMAXA’s market positioning in Ukraine and the region, as well as his strategic priorities to further propel the eye-catching development pace of this ambitious company and fully establish AMAXA as a recognized leader in its core market niches.
Could you please introduce AMAXA to our international readers and explain what is the company’s positioning in the Ukrainian market?
"Amaxa relies on a comprehensive portfolio encompassing both in-house developed medicines and in-licensed products, while we also pay the utmost attention to ensure our portfolio is tailored to the specificities and needs of each country we operate in."
